 CytoSorbents Corporation NASDAQ:CTSO, a critical care immunotherapy leader specializing in blood purification, announced today that it was awarded a Defense Health Agency Small Business Technology Transfer STTR Phase III contract, valued at up to 2,897,172 over 2 years, to advance its HemoDefend-BGA plasma and whole blood adsorber to human clinical trials. The program, entitled Development of a Highly Efficient Adsorber to Remove Anti-A and Anti-B Antibodies from Blood and Plasma for Transfusion, is being funded by the U.S. Army Medical Research and Development Command USAMRDC office of the Congressionally Directed Medical Research Programs CDMRP. This follows the successful completion of Phase I and II STTR contracts of approximately 1.15 million with researchers at Penn State University, previously funded by the U.S. Army Medical Research Acquisition Activity USAMRAA and the U.S. Army Medical Research and Material Command USAMRMC. 